UPDATE : Monday, June 24, 2019
상단여백
Latecomer experimental drug no better than Dupixent in trial by Kim Yun-mi 2019-06-24 15:49
Daewoong wins new indications for Nabota by Lee Han-soo 2019-06-24 14:47
Kang Stem Biotech completes P3 trials for stem cell-based atopy treatment by Lee Han-soo 2019-06-24 12:19
Anti-cancer Sutene could cause central nervous system abnormality in fetus by Lee Hye-seon 2019-06-24 11:35
Boryung calls off ₩83-billion supply contract in Jordan by Lee Han-soo 2019-06-21 18:00
라인
MSD’s antibiotic Zerbaxa fails to get insurance coverage by Kim Eun-young 2019-06-21 14:13
‘Customized strategies needed for fast-changing Chinese drug regulation’ by Jeong Sae-im 2019-06-21 14:12
Off-label use of Mabthera Inj. denied by Kim Yun-mi 2019-06-20 15:49
‘Korean cancer researchers have risen to world-class level’ by Kim Yun-mi 2019-06-20 15:04
AbbVie unveils data from upadacitinib phase-3 studies of rheumatoid arthritis by Lee Han-soo 2019-06-19 16:27
라인
Hanmi launches osteoarthritis injection in US by Lee Han-soo 2019-06-19 14:52
Genexine to merge with Toolgen by Lee Han-soo 2019-06-19 14:24
‘Keytruda will become most sold orphan drug worldwide by 2024’ by Kim Yun-mi 2019-06-19 11:11
ABL Bio releases latest data on Parkinson's disease treatment by Lee Han-soo 2019-06-18 17:16
‘Yuhan’s Lazertinib promising as 1st-line therapy for NSCLC’ by Jeong Sae-im 2019-06-18 14:43
라인
LEO Pharma Korea names new CEO by Lee Han-soo 2019-06-18 14:36
SK Biopharmaceutical's sleepiness treatment commercially available in US by Lee Han-soo 2019-06-18 13:42
Korean biosimilars take on original drugs in Europe by Jeong Sae-im 2019-06-17 15:26
AstraZeneca to invest $630 million in Korean biohealth sector by Kim Yun-mi 2019-06-17 11:33
Daewoong to develop hearing loss treatment using ion-channel platform tech by Lee Han-soo 2019-06-14 17:27
여백
여백
여백
Back to Top